Investors

Press Releases

Press Releases

March 24, 2020
Phase 3 study of antolimab for the treatment of eosinophilic gastritis and/or eosinophilic duodenitis (previously referred to as eosinophilic gastroenteritis) Phase 2/3 study of antolimab for the treatment of eosinophilic esophagitis Phase 1 study of subcutaneously administered antolimab in healthy

Copyright West LLC. Minimum 15 minutes delayed.